Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1676-1682

  Schwieler, Jonas H ^a   Kahan, Thomas ^b   Wallén, Nils H ^b   Nussberger, Jürg ^c   Hjemdahl, Paul ^b  

^a Department of Medicine Solna   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

coagulation; enalapril; endothelial function; hypertension; inflammation; losartan; platelet function; renin angiotensin system

Indexed keywords

ADENOSINE DIPHOSPHATE; ANGIOTENSIN II; C REACTIVE PROTEIN; ENALAPRIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOSARTAN; PADGEM PROTEIN; PLACEBO; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ADHESION PROTEIN 1; VON WILLEBRAND FACTOR;

ADULT; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; EXERCISE; EXERCISE TEST; FEMALE; HUMAN; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REST; STRESS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 84880572161     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283617310     Document Type: Article

References (42)

1. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscl Thromb Vasc Biol 2003; 23:2131-2137.
2. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115:3378-3384.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
4. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e89S-e119S.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
6. Blann AD, Nadar S, Lip GYH. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 42:1-7.
7. Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ Res 1981; 51:314-320.
8. Crabos M, Bertschin S, Buhler FR, Rogg H, Evequoz D, Eberhard M, Erne P. Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens 1993; 11 (Suppl 5):S230-S231.
9. Larsson PT, Schwieler JH, Wallen NH, Hjemdahl P. Acute effects of angiotensin II on fibrinolysis in healthy volunteers. Blood Coagul Fibrinolysis 1999; 10:19-22.
10. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000; 11:61-69.
11. Booz GW. Cardiac angiotensin AT2 receptor: what exactly does it do? Hypertension 2004; 43:1162-1163.
12. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339:1285-1292.
13. Cruden NL, Newby DE. Clots, kinins and coronaries. Atherosclerosis 2005; 183:189-198.
14. Murphey LJ, Malave HA, Petro J, Biaggioni I, Byrne DW, Vaughan DE, et al. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombininduced platelet aggregation in humans. J Pharmacol Exp Ther 2006; 318:1287-1292.
15. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, Jimenez AM, Gonzalez-Fernandez F, Rico LA, et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17:447-452.
16. Monton M, Jimenez A, Nu'nez A, Lopez-Blaya A, Farré J, Gomez J, et al. Comparative effects of angiotensin II AT-1 type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35:906-913.
17. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86:1188-1192.
18. Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, Schmidt B, et al. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Arterioscl Thromb Vasc Biol 2007; 27:1184-1190.
19. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40:521-527.
20. Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies. Circulation 2006; 114:1863-1872.
21. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J 1997; 18:807-815.
22. Li N, Wallen NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100:1374-1379.
23. Hjemdahl P, von Kanel R. Haemostatic effects of stress. In: Hjemdahl P, Rosengren A, Steptoe A, editors. Stress and cardiovascular disease. UK: Springer; 2011. pp. 89-110.
24. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurements of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986; 8:476-482.
25. Torsellini A, Becucci A, Citi S, Cozzolino F, Guidi G, Lombardi V, et al. Effects of pressure excursions on human platelets. In vitro studies on b-thromboglobulin (b-TG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation. Haematologica 1982; 67:860-866.
26. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984; 6:840-843.
27. Islim IF, Bareford D, Beevers DG. A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension. Platelets 2001; 12:274-278.
28. Hernandez-Hernandez R, Armas-Padilla MC, Velasco M, Carvajal AR, Armas de Hernandez MJ, Guerrero-Pajuelo J, Pacheco B. Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int J Clin Pharmacol Ther 1999; 37:323-331.
29. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991; 17:13-19.
30. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78:241-246.
31. Remková A, Kratochvilová H, Durina J. Impact of the therapy by reninangiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 2008; 5:338-345.
32. Yamada K, Hirayama T, Hasegawa Y. Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2007; 16:225-231.
33. Pathansali R, Smith NM, Bath PM. Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study. Platelets 2001; 12:144-1149.
34. Verma S, Lonn EM, Nanji A, Browne K, Ward R, Robertson A, et al. Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results. Can J Cardiol 2009; 25:e236-e240.
35. Pahor M, Franse LV, Deitcher SR, Cushman WC, Johnson KC, Shorr RI, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105:457-461.
36. Agabiti Rosei E, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) Study Investigators. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with noninsulin-dependent diabetes mellitus. J Hypertens 2005; 23:435-444.
37. Zappe DH, Sowers JR, Hsueh WA, Haffner SM, Deedwania PC, Fonseca VA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008; 10:894-903.
38. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H. Comparative effects of AT1-antagonism and angiotensinconverting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44:362-368.
39. Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103-1107.
40. Krysiak R, Okopień B. Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Reps 2008; 60:514-523.
41. Hlubocká Z, Umnerová V, Heller S, Peleska J, Jindra A, Jachymová M, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16:557-562.
42. Skurk T, Lee YM, Nicuta-Rolfs TO, Haastert B, Wirth A, Hauner H. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. Diabetes Obes Metab 2004; 6:56-62.